Unravelling the benefit against the risk of long-term dual antiplatelet therapy

Current Opinion in Cardiology

Volumn 26, Issue SUPPL. 1, 2011, Pages

  Bolognese, Leonardo ^a   Angiolillo, Dominick J ^b  

^a Arezzo Hospital   (Italy)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Aspirin; Clopidogrel; Long term dual antiplatelet therapy; Prasugrel; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO; PRASUGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEART DEATH; HEART INFARCTION; HUMAN; ISCHEMIA; LOADING DRUG DOSE; MONOTHERAPY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS;

ASPIRIN; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 82555202512     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/01.hco.0000409964.20588.8c     Document Type: Article

References (34)

1. Van Belle E, Lablanche JM, Bauters C. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis. Circulation 1998; 97:26-33. (Pubitemid 28036151)
2. Goldstein JA, Demetriou D, Grines. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000; 343:915-922.
3. Ault KA, Cannon CP, Mitchell J. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in myocardial infarction. J Am Coll Cardiol 1999; 33:634-639.
4. Braunwald E, Angiolillo D, Bates E, et al. The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin Cardiol 2008; 31(3Suppl 1):I-17-I-20. (Pubitemid 351442477)
5. van Domburg RT, Foley DP, de Feyter PJ, et al. Long-term clinical outcome after coronary balloon angioplasty: identification of a population at low risk of recurrent events during 17 years of follow-up. Eur Heart J 2001; 22:934-941. (Pubitemid 32625216)
6. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339:436-443.
7. Chan MY, Sun JL, Newby LK. Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction. Circulation 2009; 119:3110-3117.
8. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002; 324:71-86.
9. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348:1329-1339.
10. Ringleb PA, Bhatt DL, Hirsch AT. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004; 35:528-532. (Pubitemid 38174442)
11. Bhatt DL, Fox KA, Hacke W. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:1706-1717.
12. Yusuf S, Zhao F, Mehta SR, et al. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502. (Pubitemid 32758501)
13. Steinhubl SR, Berger PB, Mann JT 3rd. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411-2420. (Pubitemid 35340537)
14. COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366:1622-1632.
15. Sabatine MS, Cannon CP, Gibson CM, et al., for the CLARITY-TIMI 28 investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352:1179-1189. (Pubitemid 40397259)
16. Yusuf S, Mehta SR, Zhao F, et al. The Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003; 107:966-972.
17. Mehta SR, Yusuf S, Peters RJ. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358:527-533. (Pubitemid 32772726)
18. Eriksson P. Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the 'Emperor's New Clothes' revisited. Eur Heart J 2004; 25:720-722. (Pubitemid 38647930)
19. Berger PB, Bhatt DL, Fuster V. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 2010; 121:2575-2583.
20. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329:673-682.
21. Sørensen R, Hansen ML, Abildstrom SZ. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374:1967-1974.
22. García Rodríguez LA, Lin KJ, Hernández-Díaz S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 2011; 123:1108-1115.
23. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 2006; 97:38-43. (Pubitemid 41828120)
24. Vivas D, Angiolillo DJ. Platelet P2Y12 receptor inhibition: an update on clinical drug development. Am J Cardiovasc Drugs 2010; 10:217-226.
25. Brandt JT, Payne CD, Wiviott SD. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153:66.e9-66.e16.
26. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, et al., PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116:2923-2932. (Pubitemid 350291199)
27. Wiviott SD, Braunwald E, McCabe C.H. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-2015. (Pubitemid 350106708)
28. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373:723-731.
29. Murphy SA, Antman EM, Wiviott SD. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008; 29:2473-2479.
30. Gurbel PA, Bliden KP, Butler K. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121:1188-1199.
31. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-1057.
32. Cardiovascular and Renal Drugs Advisory Committee. Meeting; 2009 Feb 03; College Park (MD): Food and Drug Administration, Center for Drug Evaluation and Research. http://www.fda.gov.ohrms/DOCKETS/ac/cder09.html#CardiovascularRenal. [Accessed 8 June 2011]
33. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011; 124:544-554.
34. Antman EM, Wiviott SD, Murphy SA. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am CollCardiol 2008; 51:2028-2033. (Pubitemid 351689056)